Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CTAD 2022 | Phase II clinical trial of SAGE-718 for the treatment of MCI and early AD

SAGE-718 is a positive allosteric modulator of the NMDA receptor and is being investigated for its potential to restore NMDA tone and improve cognitive symptoms in patients with mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease (AD). Aaron Koenig, MD, Sage Therapeutics Inc., Cambridge, MA, presents findings from the open-label Phase II LUMINARY trial (NCT04602624), in which 26 people with MCI or early AD (Clinical Dementia Rating Scale score of 0.5 or 1.0) received an oral tablet of SAGE-718 once daily for two weeks. The drug was found to be well-tolerated with no safety concerns. Multiple assessments were used to test cognitive performance in participants and at day 14, improvements were observed across tests of executive functioning, memory, and learning. An overall trend of improved performance was seen in all tests of executive functioning. This interview took place at the Clinical Trials on Alzheimer’s Disease Congress 2022 in San Francisco.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


•Aaron Koenig is an employee of Sage Therapeutics, Inc., and may hold stock and/or stock options.
•The LUMINARY and LIGHTWAVE studies are sponsored by Sage Therapeutics, Inc.
•SAGE‐718 is an investigational drug and is not approved by the US Food and Drug Administration or any other regulatory agency as safe and effective for any use.